-
Orexo AB et al v. Sun Pharmaceuticals Industries Limited et al DC CAFC
- 3:20-cv-12588
- D.N.J.
- Judge: Georgette Castner
+1
- Filed: 09/11/2020
- Closed: 07/20/2023
- Latest Docket Entry: 09/06/2023
- PACER
- Docket updated daily
2
Plaintiffs
4
Defendants
5
Accused
Products
5
Patents-in-Suit
1,043
Days in
Litigation
-
Orexo AB et al v. Sun Pharmaceuticals Industries Limited et al DC CAFC
- 3:20-cv-12588
- D.N.J.
- Judge: Georgette Castner
+1
- Filed: 09/11/2020
- Closed: 07/20/2023
- Latest Docket Entry: 09/06/2023
- PACER
- Docket updated daily
Cause of Action
Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 2 |
The composition as claimed in claim 1 wherein the disintegrant is selected from the group of croscarmellose sodium, sodium starch glycolate, crosslinked polyvinylpyrrolidone and mixtures thereof.
|
Enforceable and Valid
Entry 430 |
| 16 |
The composition as claimed in claim 1, wherein the microparticles of buprenorphine or salt thereof are in associative admixture with the particles of weak acid.
|
Enforceable and Valid
Entry 430 |
-
Infringement
Sun Pharmaceutical Industries, Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| buprenorphine/naloxone sublingual tablets) at doses of 11.4/2.9 mgbuprenorphine/naloxone sublingual tablets) at doses of 1.4/0.36 mgbuprenorphine/naloxone sublingual tablets) at doses of 2.9/0.71 mgbuprenorphine/naloxone sublingual tablets) at doses of 5.7/1.4 mgbuprenorphine/naloxone sublingual tablets) at doses of 8.6/2.1 mg | US 9,439,900 B2 |
2, 16
|
Infringement
Entry 430
|
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| buprenorphine/naloxone sublingual tablets) at doses of 11.4/2.9 mgbuprenorphine/naloxone sublingual tablets) at doses of 1.4/0.36 mgbuprenorphine/naloxone sublingual tablets) at doses of 2.9/0.71 mgbuprenorphine/naloxone sublingual tablets) at doses of 5.7/1.4 mgbuprenorphine/naloxone sublingual tablets) at doses of 8.6/2.1 mg | US 9,439,900 B2 |
2, 16
|
Infringement
Entry 430
|
Sun Pharma Global
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| buprenorphine/naloxone sublingual tablets) at doses of 11.4/2.9 mgbuprenorphine/naloxone sublingual tablets) at doses of 1.4/0.36 mgbuprenorphine/naloxone sublingual tablets) at doses of 2.9/0.71 mgbuprenorphine/naloxone sublingual tablets) at doses of 5.7/1.4 mgbuprenorphine/naloxone sublingual tablets) at doses of 8.6/2.1 mg | US 9,439,900 B2 |
2, 16
|
Infringement
Entry 430
|
Sun Pharma Global Fze
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| buprenorphine/naloxone sublingual tablets) at doses of 11.4/2.9 mgbuprenorphine/naloxone sublingual tablets) at doses of 1.4/0.36 mgbuprenorphine/naloxone sublingual tablets) at doses of 2.9/0.71 mgbuprenorphine/naloxone sublingual tablets) at doses of 5.7/1.4 mgbuprenorphine/naloxone sublingual tablets) at doses of 8.6/2.1 mg | US 9,439,900 B2 |
2, 16
|
Infringement
Entry 430
|
